Your browser doesn't support javascript.
loading
Case Report: Transcatheter aortic valve implantation using balloon-expandable bioprosthesis in patients with severe pure aortic regurgitation on noncalcified native valves: a series of cases.
Santos, Luciano de Moura; Luz, Larissa Santos; Bastos, Vinicius Lelis; Barcelos, Tulio Assunção; Abreu, Frederico André Alves; Beck, Leonardo Cogo; Darnasser, Mohammed Jamal Aldin Hilal; Cruz, Francisco de Assis; Matos, Luis Carlos Vieira; Carvalho, Wenderval Borges.
Afiliação
  • Santos LM; Department of Interventional Cardiology, Hospital Santa Lucia Sul, Brasilia, Brazil.
  • Luz LS; Department of Interventional Cardiology, Hospital Santa Lucia Norte, Brasilia, Brazil.
  • Bastos VL; Department of Interventional Cardiology, Hospital Santa Lucia Sul, Brasilia, Brazil.
  • Barcelos TA; Department of Interventional Cardiology, Hospital Santa Lucia Sul, Brasilia, Brazil.
  • Abreu FAA; Department of Interventional Cardiology, Hospital Santa Lucia Sul, Brasilia, Brazil.
  • Beck LC; Department of Interventional Cardiology, Hospital Santa Lucia Sul, Brasilia, Brazil.
  • Darnasser MJAH; Department of Interventional Cardiology, Hospital Santa Lucia Sul, Brasilia, Brazil.
  • Cruz FA; Department of Interventional Cardiology, Hospital Santa Lucia Norte, Brasilia, Brazil.
  • Matos LCV; Department of Interventional Cardiology, Hospital Santa Lucia Sul, Brasilia, Brazil.
  • Carvalho WB; Department of Interventional Cardiology, Hospital Santa Lucia Norte, Brasilia, Brazil.
Front Cardiovasc Med ; 11: 1365181, 2024.
Article em En | MEDLINE | ID: mdl-38737717
ABSTRACT

Background:

For individuals with pure aortic regurgitation (AR), transcatheter aortic valve implantation (TAVI) is cautiously recommended only for those with a high or prohibitive surgical risk. We aimed to describe the results of a case series of transcatheter implantation of a balloon-expandable aortic valve bioprosthesis (BEV) for the treatment of noncalcified native valve AR.

Methods:

From February 2022-November 2022, we performed TAVI in patients with severe pure AR. Cases were indicated on the basis of symptoms, high/prohibitive surgical risk, or patient refusal of conventional treatment.

Results:

Five patients underwent successful TAVI. The mean age was 81.9 ± 6.6 years, 3 (60%) female and 5 (100%) in NYHA class III or IV. The baseline echocardiogram showed an ejection fraction of 49.0 ± 10.6% and left ventricular end-systolic diameter 28.5 ± 4.7 mm/m². The average area of the aortic annulus was 529.1 ± 47.0mm² and the area oversizing index was 17.6 ± 1.2%. In the 30-day follow-up, there were no cases of prosthesis embolization, annulus rupture, stroke, acute myocardial infarction, acute renal failure, hemorrhagic complication or death. One patient required a permanent pacemaker and another had a minor vascular complication. The clinical follow-up were 19.8 months (16.7-21.8). During this period, all patients remained alive and in NYHA class I or II. One of the patients developed a moderate paravalvular leak.

Conclusion:

TAVI with a BEV proved to be safe and effective in this small case series of patients with noncalcified native valve AR in a follow-up longer than 1 year.
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Cardiovasc Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Cardiovasc Med Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça